Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $578.2 million.

  • Ligand Pharmaceuticals' Retained Earnings rose 908.24% to $578.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $578.2 million, marking a year-over-year increase of 908.24%. This contributed to the annual value of $499.0 million for FY2024, which is 80.16% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Retained Earnings stood at $578.2 million, which was up 908.24% from $461.4 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Retained Earnings' 5-year high stood at $589.2 million during Q1 2024, with a 5-year trough of $410.1 million in Q1 2021.
  • For the 5-year period, Ligand Pharmaceuticals' Retained Earnings averaged around $486.2 million, with its median value being $468.8 million (2022).
  • Per our database at Business Quant, Ligand Pharmaceuticals' Retained Earnings skyrocketed by 1954.99% in 2024 and then plummeted by 2251.05% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Retained Earnings (Quarter) stood at $449.1 million in 2021, then rose by 0.39% to $450.9 million in 2022, then grew by 11.57% to $503.0 million in 2023, then fell by 0.8% to $499.0 million in 2024, then rose by 15.88% to $578.2 million in 2025.
  • Its Retained Earnings was $578.2 million in Q3 2025, compared to $461.4 million in Q2 2025 and $456.5 million in Q1 2025.